ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis

Published:2021-01 Issue:1 Volume:47 Page:134-138
ISSN:0748-7983
Container-title:European Journal of Surgical Oncology
language:en
Short-container-title:European Journal of Surgical Oncology

Author:

Frøysnes Ida S.,Andersson Yvonne,Larsen Stein G.,Davidson Ben,Øien Janne-Merete Torset,Julsrud Lars,Fodstad Øystein,Dueland Svein,Flatmark Kjersti

Funder

Norwegian Cancer Society

South-Eastern Norway Regional Health Authority

Fondsstiftelsen

Oslo University Hospital

Publisher

Elsevier BV

Subject

Oncology,General Medicine,Surgery

Reference18 articles.

1. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer;van Gestel;Eur J Surg Oncol,2014

2. Peritoneal carcinomatosis from colorectal cancer;Jayne;Br J Surg,2002

3. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study;Sadeghi;Cancer,2000

4. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer;Verwaal;Ann Surg Oncol,2008

5. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study;Mahteme;Br J Canc,2004

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in Biological Research and Treatment of Pseudomyxoma Peritonei;Cancers;2024-04-03

2. Peritoneal Metastasis: A Dilemma and Challenge in the Treatment of Metastatic Colorectal Cancer;Cancers;2023-11-29

3. Targeted inhibition of protein synthesis renders cancer cells vulnerable to apoptosis by unfolded protein response;Cell Death & Disease;2023-08-26

4. Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes;Cancers;2023-04-20

5. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model;International Journal of Molecular Sciences;2023-02-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3